Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Nathan Dahl and John DeSisto.

 
Connection Strength
 
 
 
0.166
 
  1. Balakrishnan I, Madhavan K, Pierce A, Michlin J, Brunt B, Lakshmanachetty S, Wang D, DeSisto J, Nuss ZJ, Davidson N, Walker F, Suresh A, Donson A, Sanford B, Jones KL, Danis EP, Mitra SS, Green AL, Dahl N, Vibhakar R, Venkataraman S. Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma. Cancer Res. 2025 May 27.
    View in: PubMed
    Score: 0.062
  2. Alimova I, Wang D, DeSisto J, Danis E, Lakshmanachetty S, Prince E, Murdock G, Pierce A, Donson A, Balakrishnan I, Serkova N, Lin H, Foreman NK, Dahl N, Venkataraman S, Vibhakar R. SIRT2 regulates the SMARCB1 loss-driven differentiation block in ATRT. Mol Cancer Res. 2025 Feb 17.
    View in: PubMed
    Score: 0.061
  3. Green AL, Flannery P, Hankinson TC, O'Neill B, Amani V, DeSisto J, Knox A, Chatwin H, Lemma R, Hoffman LM, Mulcahy Levy J, Raybin J, Hemenway M, Gilani A, Koschmann C, Dahl N, Handler M, Pierce A, Venkataraman S, Foreman N, Vibhakar R, Wempe MF, Dorris K. Preclinical and clinical investigation of intratumoral chemotherapy pharmacokinetics in DIPG using gemcitabine. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa021.
    View in: PubMed
    Score: 0.043
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)